Smith Assortment | Archive Photographs | Getty Photos
Weight problems drug developer Metsera stated on Friday that it had accepted Pfizer‘s $10 billion acquisition supply, in what might spell the tip of a bidding battle between the New York-based pharma large and rival Novo Nordisk that erupted during the last week.
Pfizer had appeared to have locked up this acquisition in September earlier than Novo jumped in final week, sparking a strategic struggle for a coveted asset within the rising weight reduction market. Pfizer is making an attempt to realize a toehold in that market to beat previous in-house stumbles in growing weight-loss medicine.
Pfizer stated it could pay $86.25 per share in money, a premium of three.69% to Metsera’s Friday shut. The supply contains $65.60 per share in money and a contingent worth proper (CVR) entitling holders to extra funds of as much as $20.65 per share in money.
Novo desires to get well its once-commanding place in weight problems medicine it misplaced to Eli Lilly It’s unclear if they are going to make one other supply, or if Metsera would entertain one other bid. The corporate, in its Friday assertion, stated Novo’s proposal presents “unacceptably excessive authorized and regulatory dangers” in comparison with the proposed merger with Pfizer.
Metsera’s board beneficial its shareholders approve the amended Pfizer supply. In a press release, Pfizer stated it was happy to have reached an settlement with Metsera.
The biotech firm at the moment loses cash and analysts anticipate additional losses whereas its medicine are nonetheless in growth.
The bidding battle between Pfizer and Novo took the worth from Pfizer’s $7.3 billion supply in September to the present worth. It had escalated right into a authorized and strategic standoff, with Novo searching for to wrest Metsera from Pfizer’s grip via an advanced deal construction that has drawn scrutiny from regulators.
Metsera’s experimental weight problems medicine MET-097i – a GLP-1 injectable – and MET-233i, which mimics the pancreatic hormone amylin, are projected to achieve $5 billion in mixed peak gross sales, in response to Leerink Companions analyst David Risinger.